Skip to main content
. 2024 Nov 16;50(5):e20240302. doi: 10.36416/1806-3756/e20240302

Table 1. Demographic characteristics of the study sample.a .

Variable Total Non-COVID-19 COVID-19 p
Crude* Adjusted**
Number of patients 76 (100%) 45 (59.2%) 31 (40.8%)
Age, years 71 (56-82) 75 (69-85) 58 (46-76) 0.01 0.03
Male 46 (60.5%) 26 (57.8%) 20 (64.5%) 0.55 0.49
Charlson Comorbidity Index 4 (2-6) 5 (4-6) 2 (1-4) < 0.01 0.04
APACHE II score 14 (9-20) 18 (13-22) 9 (8-14) < 0.01 < 0.01
Pre-ICU admission length of stay, days 1 (0-4) 1 (0-5) 2 (1-4) 0.54 0.63
Duration of IMV before SBT, days 7 (4-10) 5 (3-8) 10 (7-13) < 0.01 0.01
PaCO2, mmHg 41 (37-46) 39 (36-44) 42 (40-48) 0.02 0.08
Duration of SBT, min 50 (30-60) 50 (35-60) 60 (30-69) 0.18 0.23
Use of vasopressor 74 (97.4%) 44 (97.8%) 30 (96.8%) > 0.99 0.94
Need for RRT 21 (27.6%) 15 (33.3%) 6 (19.4%) 0.18 0.12
Systemic corticosteroid use 63 (82.9%) 32 (71.1%) 31 (100%) 0.01 0.01
SBT on PSV 40 (52.5%) 11 (24.4%) 29 (93.5%) < 0.01 < 0.01
Extubation success within 72 h 57 (75%) 35 (77.8%) 22 (71%) 0.50 0.47
Tracheostomy 14 (18.4%) 5 (11.1%) 9 (29%) 0.04 0.04
Simple weaning 47 (61.8%) 34 (75.6%) 13 (41.9%) < 0.01 < 0.01
Duration of IMV, days 8 (4-12) 6 (3-8) 11 (9-23) < 0.01 < 0.01
Length of ICU stay, days 17 (12-29) 15 (10-23) 23 (16-36) < 0.01 < 0.01
Length of hospital stay, days 35 (21-51) 32 (18-51) 38 (23-57) < 0.01 0.03
Death during hospitalization 22 (29.3%) 6 (20%) 16 (35.6%) 0.14 0.08
Discharge from the ICU 57 (75%) 25 (80.6%) 32 (71.1%) 0.34 0.31

IMV: invasive mechanical ventilation; SBT: spontaneous breathing trial; RRT: renal replacement therapy; and PSV: pressure support ventilation. aData expressed as n (%) or median (IQR). *Pearson’s chi-square test or Fisher’s exact test for qualitative variables and the Mann-Whitney test for quantitative variables. **Multivariate Poisson regression to adjust for potential influences of covariates.